Show simple item record

dc.contributor.authorToor, S
dc.contributor.authorElkord, Eyad
dc.date.accessioned2018-01-27T19:07:42Z
dc.date.available2018-01-27T19:07:42Z
dc.date.issued2017
dc.identifier.citationComparison of myeloid cells in circulation and in the tumor microenvironment of patients with colorectal and breast cancers. 2017, 2017:7989020 J Immunol Resen
dc.identifier.issn2314-7156
dc.identifier.pmid29230424
dc.identifier.doi10.1155/2017/7989020
dc.identifier.urihttp://hdl.handle.net/10541/620797
dc.description.abstractWe have previously reported levels of myeloid cells in the periphery and in the tumor microenvironment (TME) of patients with primary breast cancer (PBC) and colorectal cancer (CRC). We found that both PBC and CRC patients have significantly higher levels of granulocytic and immature myeloid cells in the TME. Additionally, we reported an expansion of circulating granulocytic myeloid cells in CRC patients, but not in PBC patients. In this report, we compared levels of myeloid cells between these two common cancers and have added data from more cancer patients. We also investigated associations between clinical stage/histological grade of tumors and levels of myeloid cells in cancer patients. We found that although granulocytic myeloid cells were expanded in the TME of both PBC and CRC patients, the levels of these cells were significantly higher in the TME of CRC patients. Moreover, our results indicate that increased levels of circulating granulocytic myeloid cells are associated with poorly differentiated tumors in CRC patients. Taken together, this work suggests that CRC patients may benefit more from the development of therapeutic agents to promote myeloid cell differentiation or inhibition for the reversal of immune suppression.
dc.language.isoenen
dc.rightsArchived with thanks to Journal of immunology researchen
dc.titleComparison of myeloid cells in circulation and in the tumor microenvironment of patients with colorectal and breast cancers.en
dc.typeArticleen
dc.contributor.departmentCancer Research Center, Qatar Biomedical Research Institute, College of Science and Engineering, Hamad Bin Khalifa University, Qatar Foundation, Doha, Qatar.en
dc.identifier.journalJournal of Immunology Researchen
refterms.dateFOA2018-12-17T15:12:34Z
html.description.abstractWe have previously reported levels of myeloid cells in the periphery and in the tumor microenvironment (TME) of patients with primary breast cancer (PBC) and colorectal cancer (CRC). We found that both PBC and CRC patients have significantly higher levels of granulocytic and immature myeloid cells in the TME. Additionally, we reported an expansion of circulating granulocytic myeloid cells in CRC patients, but not in PBC patients. In this report, we compared levels of myeloid cells between these two common cancers and have added data from more cancer patients. We also investigated associations between clinical stage/histological grade of tumors and levels of myeloid cells in cancer patients. We found that although granulocytic myeloid cells were expanded in the TME of both PBC and CRC patients, the levels of these cells were significantly higher in the TME of CRC patients. Moreover, our results indicate that increased levels of circulating granulocytic myeloid cells are associated with poorly differentiated tumors in CRC patients. Taken together, this work suggests that CRC patients may benefit more from the development of therapeutic agents to promote myeloid cell differentiation or inhibition for the reversal of immune suppression.


Files in this item

Thumbnail
Name:
7989020.pdf
Size:
2.518Mb
Format:
PDF
Description:
Full text, Open Access article

This item appears in the following Collection(s)

Show simple item record